Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
In an international, multicenter, open-label study, the long-term efficacy and safety of gabapentin (GBP, Neurontin) as add-on therapy were investigated in 203 patients with partial seizures refractory to standard antiepileptic drugs (AEDs). All patients enrolled in this study had experienced improved seizure control with GBP in one of four previous, short-term studies. Patients received mean Gabapentin is 1 of many antiseizure medications available for the treatment of epilepsy in adults; however, there are potential risks associated with its use. Therefore, it is important to determine the place of therapy of gabapentin in the treatment of epilepsy. OBJECTIVE: To assess the effect of different doses of gabapentin (GBP) on cognitive function in treated epileptic patients. METHODS: Twenty seven patients with refractory partial seizures commenced a double blind, dose ranging, placebo controlled, Abstract Eleven dogs diagnosed with refractory idiopathic epilepsy were treated orally with gabapentin for a minimum of three months at an initial dose of 10 mg/kg every eight hours. They were all experiencing episodes of generalised tonic-clonic seizures and had been treated chronically with a combination of phenobarbital and potassium bromide at doses sufficient to reach acceptable Control of canine epilepsy may only be possible in up to 70-80 % of cases on phenobarbitone (PB). This therapy may improve if combination therapy with potassium bromide (KBr) is used. More recently, several human drugs, such as gabapentin and levetiracetam, have been evaluated for seizure therapy in veterinary patients. This article will discuss anticonvulsant drug use in dogs with so-called Seizures are a common problem in veterinary medicine. Control of canine epilepsy is only possible in up to 70 – 80 % of cases on phenobarbitone (PB). This therapy may improve if combination therapy with potassium bromide (KBr) is used. More recently, several human drugs, such as gabapentin and levetiracetam, have been evaluated for seizure therapy in veterinary patients. This article will There are two clinical reports of gabapentin use as an add-on drug for dogs with refractory epilepsy. Overall, the responder rate of these dogs was between 41% and 55%. Abstract Gabapentin, administered as add-on therapy, was safe and effective in this 12-week, multicenter, placebo-controlled, parallel-group study in 306 patients with refractory partial epilepsy. For patients in each gabapentin treatment group (600, 1,200, or 1,800 mg/d), the mean response ratio was significantly better than that of a placebo Objective: To assess whether there is a change in seizure activity in dogs with refractory epilepsy that are receiving appropriate doses of phenobarbitone and/or potassium bromide, when gabapentin is added to the therapeutic regimen. Design: A prospective study of 17 dogs with a refractory seizure disorder, 16 of which have idiopathic epilepsy. FRIDAY, July 11, 2025 A drug used to treat seizures, nerve pain and restless leg syndrome might be linked with increased risk of dementia, a new study says. Reg The efficacy of gabapentin in the management of refractory canine epilepsy has been evaluated in two studies (Platt et al, 2006; Govendir et al, 2005). The first study reported 11 dogs that were already receiving phenobarbital and potassium bromide at therapeutic serum concentrations and were deemed to have poor seizure control (Platt et al, 2006). An effective epilepsy treatment plan for dogs should reduce seizure frequency, minimize adverse drug effects, and maximize quality of life. The second study evaluated 17 dogs with refractory seizures that were administered gabapentin at a dose of 35 to 50 mg/kg/day divided twice or three times daily, also in conjunction with phenobarbital and potassium bromide (16 dogs) or phenobarbital alone (1 dog).9 This study found no significant decrease in the number of seizures over the The efficacy of gabapentin (Neurontin ®) in generalized seizures was evaluated in this 14 week, double-blind, placebo-controlled, parallel-group, add-on, multicenter study. A total of 129 patients with refractory generalized seizures were randomized to receive either placebo or 1200 mg/day gabapentin as add-on therapy. Patients received their standard regimens of antiepileptic drugs (AEDs Further trials are needed to assess the long‐term effects of gabapentin, and to compare gabapentin with other add‐on drugs. Plain language summary Gabapentin as an add‐on for drug‐resistant focal epilepsy Background Epilepsy is a disorder where recurrent seizures (fits) are caused by abnormal electrical discharges from the brain. Delahoy and colleagues 29 showed that in patients with refractory partial epilepsy, pregabalin was more effective than gabapentin on clinical response and the number of seizure-free days over the last 28 days. Similarly, a retrospective study by Gidal, et al. evaluated gabapentin as an add on therapy and reported a reduction in seizure frequency and improved seizure control in patients with refractory epilepsy [3]. Background: Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs. Gabapentin (GBP) is one of several novel anti-epileptic drugs effective as an add-on therapy for intractable seizures but has not been studied in patients with cerebral tumours. The National Institute for Health and Care Excellence (NICE) recommends gabapentin only as adjunctive treatment for refractory focal seizures in children, young people, and adults and for treatment of children and young people with benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, or late‐onset childhood occipital epilepsy In 2023, Schiller et al 39 performed a single-center, randomized, double-blind, placebo-controlled crossover clinical trial examining memantine therapy in pediatric patients with developmental and epileptic encephalopathy (DEE)—severe epilepsy with childhood onset characterized by refractory seizures, developmental regression, and EEG abnormalities. Patients with DEE frequently have genetic
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |